Synapse (New York, N.Y.)
December 1, 2005
Matthew D Schmidt, Mark S Schmidt, Eduardo R Butelman et al.
85 citations
Salvinorin A, a potent hallucinogen from Salvia divinorum, is rapidly eliminated from the body after intravenous administration in rhesus monkeys, with an average elimination half-life of about 57 minutes. Pharmacokinetic differences in distribution half-life, elimination half-life, and area under the curve were observed between males and females, suggesting potential sex differences in the drug's effects. The presumed major metabolite, salvinorin B, was not detected in the study, though it is known to accumulate outside the body.
Bioorganic & medicinal chemistry letters
October 18, 2004
Kevin Tidgewell, Wayne W Harding, Mark Schmidt et al.
68 citations
Salvinorin A, a hallucinogen from Salvia divinorum, may serve as a therapeutic for stimulant abuse, but no methods exist to detect it or its metabolites in biological fluids. This work describes a straightforward synthesis of a deuterium-labeled analog of salvinorin A and its use as an internal standard for detecting salvinorin A and its metabolites in biological fluids using LC-MS, providing a tool for studying its metabolism and potential therapeutic development.
Journal of natural products
January 1, 2006
Wayne W Harding, Matthew Schmidt, Kevin Tidgewell et al.
59 citations
Salvinorin A, a hallucinogen from the plant Salvia divinorum, is unique as the first non-nitrogenous compound known to bind to opioid receptors. To understand why it selectively targets kappa opioid receptors, researchers systematically altered its structure and tested the effects on receptor binding and activity. This work describes chemical transformations of salvinorin A, including a semisynthesis of salvinicins A and B. It also identifies compound 10a as the first neoclerodane diterpene with delta opioid antagonist activity, providing new tools for studying opioid receptor interactions.